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In vitro studies have shown that crosslinking of the B-cell receptor
(BCR) by anti-IgM monoclonal antibody (mAb) can have either
stimulatory or inhibitory effects depending on the maturation state
of the cell (De Franco et al, 1982; Hasbold and Klaus, 1990.). Of
particular interest in the field of immunotherapy is that crosslinking
of the BCR on B lymphoma cells can induce inhibitory signals that
may result in cell cycle arrest and apoptosis (Hasbold and Klaus,
1990; Marches et al, 1995). There is growing evidence that such
transmembrane signalling is critical to much of the therapeutic
success of anti-idiotype (Id) mAb in the treatment of non-Hodgkins
lymphoma (NHL). For example the study by Vuist et al (1994)
highlighted the close correlation between the therapeutic success of
anti-Id mAb in NHL and the ability of the treatment mAb to stimu-
late protein tyrosine phosphorylation in frozen archive tumour
material. Since tyrosine phosphorylation following crosslinking of
surface immunoglobulin (Ig) is one of the first steps in the cascade
of intracellular signalling events (Gold et al, 1991; Sefton and
Campbell, 1991), this positive correlation suggests that the key to
the success of anti-Id mAb may stem from their ability to crosslink
surface Ig and deliver a direct anti-proliferative signal to the
tumour. The importance of crosslinking was further suggested by
the observation that although cells from non-responding patients
could not be induced to signal with anti-Id mAb, they were respon-
sive to stimulation with a polyclonal anti-m Ab, which, because it
recognizes multiple epitopes on the BCR, possesses a far greater
potential for crosslinking than a single mAb.
While these results indicate the importance of crosslinking in the
inhibitory action of anti-Id mAb, the extent of crosslinking neces-
sary for achieving inhibition, and the antibody binding require-
ments, have not been fully defined. In this paper, we describe the
sensitivity of a panel of Burkitt’s lymphoma cell lines to the growth
inhibitory effects of anti-IgM mAb, and a series of experiments
designed to look at the effects of IgM domain specificity, BCR
crosslinking, and hyper-crosslinking on growth inhibition.
MATERIALS AND METHODS
Cell lines and antibodies
The Burkitt’s lymphoma cell lines Daudi, Ramos, Ramos-sublines
RA.1 and EHRB, Raji, Namalwa, MUTU-I and MUTU-61E
(kindly given by Dr A Milner and Prof. Chris Gregory,
Birmingham, UK), Nalm-6 (kindly given by Dr Bill Cushley,
Glasgow, UK) and Bristol-8 cells were used in this study. All cell
lines were maintained in supplemented RPMI-1640 [RPMI-1640
medium containing glutamine (2 mM), pyruvate (1 mM), penicillin
and streptomycin (100 IU ml–1), fungizone (2 mg ml–1) and 10%
fetal calf serum (FCS) (Myoclone) (Gibco Ltd, Paisley, UK)].
Monoclonal antibodies used in these studies included: anti-m,
M15/8, ZL7/5 and Mc41/24G10 (all anti-Fcm), and anti-l, M15/2
and Mc24/1C6, all raised in this laboratory (Bonardi et al, 1993;
Zhang et al, 1995), the anti-Fabm antibodies M-2E6 (ATCC,
Rockville, MA, USA) and XG9 (kindly given by Dr Patricia
Mongini, New York, NY, USA) (Rudich et al, 1988). In addition,
we used three anti-Id mAb, ZL16/1, ZL16/3 and ZL16/11, specific
for the surface IgM of the Ramos cell line and one anti-Id mAb,
ZL15/27, specific for the surface IgM of the Daudi cell line
(Zhang et al, 1995). Polyclonal sheep anti-mouse IgG was raised
at Tenovus.
All hybridoma lines secreting mAb were expanded in tissue
culture and purified from culture supernatant using a Protein A
column (Glennie et al, 1993). F(ab¢)2 fragments of IgG were
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Correspondence to: MS Craggprepared by limited proteolysis with pepsin at pH 4.0–4.2 (Glennie
et al, 1993). Fab¢ from M15/8 and Mc24/1C6 F(ab¢)2 was produced
by reduction with 20 mM 2-mercaptoethanol for 30 min at 25°C,
followed by alkylation with excess iodoacetamide.
Measurement of [3H]thymidine incorporation
Cells (5 ´ 104) were aliquoted into each well of a 96-well
microtitre plate (Gibco) and incubated in 200 ml of supplemented
RPMI medium containing the required concentration of mAb for
24 h at 37°C before pulsing overnight with 0.5 mCi [3H]thymidine
(Amersham International PLC, UK) in 50 ml RPMI as described
previously (Tutt et al, 1991). The incorporation of [3H]thymidine
into DNA was assessed by harvesting the cells onto glass
microfibre filters and washing with water. Experimental points
were determined in triplicate. The variation between triplicates
was less than 10%.
Preparation of anti-Fcm (M15/8) multimers
M15/8 F(ab¢)3 was prepared using the bis-maleimide crosslinker,
o-phenylenedimaleimide, as described by Tutt et al (1991) for the
preparation of bispecific trimers.
Hyper-crosslinking experiments
mAb at a concentration of 10 mg ml–1 were first allowed to bind to
cells at a concentration of 2.5 ´ 105 ml–1 for 15 min at 4°C. Cells
were then separated from excess unbound antibody in the super-
natant by centrifugation, and the supernatant removed. Cells were
resuspended at a concentration of 2.5 ´ 105 ml–1 in medium
containing polyclonal sheep anti-mouse IgG at 20 mg ml–1, to act
as a hyper-crosslinking reagent, plated out as 200 ml aliquots on
96-well microtitre plates, and incubated for 24 h at 37°C before
pulsing overnight with 0.5 mCi [3H]thymidine. Cells were then
harvested and incorporated radioactivity determined as described
above.
Measurement of apoptosis using propidium iodide
Samples were assessed by the method of Nicoletti et al (1991).
Briefly, aliquots of cells (106) were centrifuged for 5 min at 500 g
and then washed once in phosphate-buffered saline (PBS). The
cells were then resuspended in hypotonic fluorochrome solution
(50 mg ml–1 propidium iodide (PI), 0.1% (w/v) sodium citrate,
0.1% (w/v) Triton X-100) and incubated in the dark at 4°C
overnight or 1 h at room temperature. PI staining of DNA from 10
000 cells was detected on a FACScan flow cytometer (Becton
Dickinson) and the proportion of DNA giving fluorescence below
the G1/0 peak was taken as a measure of apoptosis.
Agarose gel DNA fragmentation analysis
Following incubation of cells under appropriate conditions,
samples containing 1–2 ´ 106 cells were harvested. Twenty
microlitres TE-SLS (10 mM EDTA, 50 mM Tris-HCl pH 8.0, 0.5%
(v/v) sodium lauryl sarkosinate (SLS, Sigma)) plus 0.5 mg ml–1
proteinase K (Sigma) was then added, and the samples incubated
for 1–2 h at 50°C. 10 ml 0.16 mg ml–1 RNase A (Sigma) was added
and samples were incubated for a further 1–2 h at 50°C. The
temperature of the samples was then increased to 70°C for addition
of 10 ml of loading buffer [10 mM EDTA, 1% (w/v) low melting
point agarose, 0.25% (w/v) bromophenol blue, 40% (w/v) sucrose].
Samples were loaded into dry wells of 1% (w/v) agarose gels
containing 0.5 mg ml–1 ethidium bromide and run either overnight
at 30–40 V or for 2–3 h at 80 V, in TAE (89 mM Tris, 89 mM boric
acid, 2 mM EDTA, pH8.4). DNA was visualized by UV light.
Radioiodination of antibodies
mAb were trace radiolabelled for binding studies using carrier-free
125I (Amersham International plc) and IODO-BEADS (Pierce
Chemicals Co., Rockford, IL, USA) as the oxidizing reagent.
Radioactivity was measured in a Rackgamma spectrometer
(LKB). The immunoreactive component of each mAb [125I]IgG
preparation was estimated by determining what fraction bound to a
large antigen excess as described by Elliot et al (1987). Typically,
mAb were found to contain 50–85% reactive material.
Binding of [125I]mAb to the cell surface
The binding of radiolabelled mAb to cells was determined as
described by Elliot et al (1987). Radiolabelled mAb were serially
diluted before incubating with cells (0.5–1.25 ´ 106 ml–1, final
volume 1 ml) in RPMI medium containing 10% FCS for 2 h at
37°C. Endocytosis of cell bound mAb was prevented by inclusion
of sodium azide (15 mM) and 2-deoxyglucose (50 mM). The cells
were separated from the aqueous phase by centrifugation through a
1.1:1 (vol/vol) mixture of dibutyl phthalate:dioctyl phthalate.
Radioactivity was measured in a Rackgamma spectrometer
(LKB).
RESULTS
Sensitivity of Burkitt’s lymphoma cell lines to anti-BCR
induced growth inhibition
In preliminary experiments, eight Burkitt’s lymphoma cell lines,
Daudi, Bristol-8, MUTU-I, MUTU-61E, Nalm-6, Namalwa,
Ramos and Raji, were assessed for their sensitivity to anti-Fcm
mAb in growth assays. The results obtained with the Ramos,
MUTU-I, and Daudi lines with the anti-Fcm mAb M15/8 are shown
in Figure 1. Of the eight lines tested, only Ramos and MUTU-I
were sensitive to M15/8, showing a 60–80% inhibition of
[3H]thymidine incorporation at a mAb concentration of 10 mg ml–1
(Figure 1A, B). Two other anti-Fcm mAb, Mc41/24G10 and ZL7/5,
had similar inhibitory activity on these particular cell lines.
The sensitivity of the eight cell lines to polyclonal anti-m Ab was
also determined. Ramos and Mutu-1 were both highly sensitive to
polyclonal anti-m, giving up to 90% inhibition of [3H]thymidine
incorporation at 10 mg ml–1 (Figure 1A, B). In addition, the Daudi
cell line was sensitive (Figure 1C) which, in the light of its insensi-
tivity to anti-Fcm mAb, was of particular interest and suggested that
the extent of crosslinking of the BCR was probably important in
determining growth arrest. The other five cell lines were insensitive
to polyclonal anti-m antibody. Four of the cell lines, Nalm-6,
Bristol-8, Raji and Namalwa, expressed relatively low to medium
levels of surface IgM compared with Ramos, Daudi, MUTU-I and
MUTU-61E (results not shown). Since each of the former group
were insensitive to growth arrest, this suggested that although a
high level of surface IgM did not guarantee anti-m mAb-induced
inhibition, it was a prerequisite for sensitivity.
Binding of mAb to B-cell surface IgM 851
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Although initial studies were performed on the Ramos line,
several Ramos sub-lines also exist. Two of these, RA.1 (a direct
EBV transformant of the original Ramos), and EHRB (a more
lymphoblastoid cell type) were assessed for anti-m mAb-induced
growth arrest. While RA.1 cells behaved in a similar manner to the
parent line, EHRB cells were found to be particularly sensitive to
growth arrest (data not shown) and furthermore succumbed to
apoptosis over a period of 24 h in culture with anti-Fcm mAb
(Table 1). EHRB cells were selected for almost all subsequent
work. Ramos cells and sublines also have the advantage of being
FcR-negative, and so in binding studies whole IgG could be used
without interference from Fc:FcR interactions.
Growth inhibition with pairs of anti-Fcm mAb
Crossblocking studies showed that the anti-Fcm mAb M15/8 and
ZL7/5 blocked the binding of each other and so bound to identical
or overlapping epitopes on the Fc region of IgM (results not
shown). The third anti-Fcm mAb, Mc41/24G10, bound to a distinct
epitope on the Fc region since its binding was blocked neither by
M15/8 nor by ZL7/5. The effect of both non-crossblocking and
crossblocking pairs of anti-Fcm mAb on DNA synthesis in EHRB
and Daudi cells was determined (Figure 2). The results show that
on EHRB cells (Figure 2A), the two non-crossblocking pairs of
anti-Fcm mAb (M15/8+Mc41/24G10, and ZL7/5+Mc41/24G10)
were markedly more potent inhibitors than the individual mAb or
the pair of crossblocking antibodies (M15/8+ZL7/5). Interestingly,
using Daudi cells (Figure 2B), which are resistant to inhibition by
single anti-Fcm mAb, pairs of non-crossblocking mAb, like poly-
clonal anti-m (Figure 1B), were quite effective and inhibited
growth by more than 70%.
Since mAb are directed to a single epitope on the Fcm region,
the most likely explanation for the enhanced response seen with
non-crossblocking pairs, is that they crosslink the surface IgM
more extensively. This interpretation would be consistent with the
potent inhibition of growth seen with polyclonal anti-m Ab (Figure
1) and suggest that Daudi cells require a higher degree of
crosslinking than EHRB in order to generate inhibitory signals.
Growth inhibition with anti-Fcm multimers
As an additional method of investigating the role of crosslinking,
the performance of Fab¢ (univalent), F(ab¢)2 (bivalent) and F(ab¢)3
(trivalent) prepared from the anti-Fcm mAb M15/8 were compared
on EHRB cells. The results are shown in Figure 3 and demonstrate
that increasing mAb valency resulted in increased growth inhibi-
tion. Thus Fab¢ fragments were ineffective, F(ab¢)2 fragments were
comparable to the parent IgG, and the F(ab¢)3 species was by far
the most effective inhibitor. The insert in Figure 3 shows the level
of DNA fragmentation achieved as a result of cells entering apop-
tosis when cultured with the different anti-m mAb fragments. The
trivalent F(ab¢)3 induced the highest level of DNA fragmentation.
This result was confirmed by measuring the extent of apoptosis in
each culture using the method of Nicoletti et al (1991) (Table 1),
which showed that the increasing growth inhibition correlated with
an increase in the level of apoptosis induced, with the M15/8 Fab¢,
F(ab¢)2 and F(ab¢)3 fragments giving 6%, 20% and 40% apoptosis.
In addition, several other criteria of apoptosis, including annexin V
positivity, chromatin condensation, cell shrinkage and apoptotic
body formation, were observed (results not shown).
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Figure 1 Growth inhibition of Ramos, MUTU-I, and Daudi cell lines following treatment with monoclonal or polyclonal anti-m antibody. Ramos (A), MUTU-I (B),
and Daudi (C) cells were incubated with antibody at the concentration shown for 24 h, and then with 0.5 mCi [3H]thymidine for 16 h. Cells were then harvested
and counted to determine incorporation of radioactivity. The results represent the mean of triplicate determinations. n n, irrelevant mAb; t, sheep anti-mouse
IgG; l, M15/8 (anti-Fcm); l l, ZL7/5 (anti-Fcm); s s, Mc41/24G10 (anti-Fcm). One of at least three similar experiments
Table 1 The induction of apoptosis in EHRB cells by anti-Fcm mAb
Experiment Treatment % Apoptoticd
None 7 ±1
Anti-Fcma 31 ± 5
Anti-Fcm multimers Anti-Fcm Fab¢b 11.5 ± 7
Anti-Fcm F(ab¢)2
b 35 ± 13
Anti-Fcm F(ab¢)3
b 47 ± 5
Hyper-crosslinking Anti-Fcmc 12 ± 6
Anti-Fcm + sheep anti-mouse IgGc 62 ± 17
Cells were incubated with treatment antibody as described below and the
level of apoptosis assessed by propridium iodide analysis. The anti-Fcm mAb
used was M15/8. a,bCells were incubated with mAb at 1 mg ml–1 for 48 h.
cCells were incubated with 10 mg ml–1 anti-Fcm mAb for 15 min, then washed
and sheep anti-mouse IgG added for 48 h as described in Figure 5. dValues
represent mean ± SD for three experiments.Binding of mAb to B-cell surface IgM 853
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Effect of hyper-crosslinking on growth inhibition
As an alternative approach to demonstrate the effect of
crosslinking IgM on B-cell growth, we used a layer of polyclonal
Ab to extensively crosslink the primary mAb once it had bound to
the cell surface. This is termed hyper-crosslinking. The protocol
used in these experiments was to allow primary mAb (10 mg ml–1)
to bind to the cell surface for 15 min, and then to remove the cells
from excess mAb by centrifugation before adding the secondary
polyclonal anti-mouse IgG Ab. The effect of hyper-crosslinking
anti-Fcm mAb was determined for both EHRB and Daudi cells,
and the results are shown in Figure 4. In EHRB cells, hyper-
crosslinking was extremely effective at inducing growth arrest
(Figure 4A), thus while the anti-Fcm mAb alone resulted in a
maximum of 20% inhibition, in the presence of the hyper-
crosslinking Ab it was increased to greater than 90%. This
enhanced growth inhibition was associated with an increase in the
level of apoptosis from 6% to 43% (Table 1). With Daudi cells
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Figure 2 Growth inhibition of EHRB and Daudi cells with pairs of anti-Fcm mAbs. EHRB (A) and Daudi (B) cells were incubated with single or pairs of anti-Fcm
mAb and [3H]thymidine as described in Figure 1. n n, irrelevant mAb; l, M15/8; l l, ZL7/5; s s, Mc41/24G10; s, M15/8 + ZL7/5; n, ZL7/5 + Mc41/24G10; 
t t, M15/8 + Ms41/24G10; t, all three anti-Fcm mAb. One of at least three similar experiments
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Figure 3 Comparison of growth inhibition of EHRB cells with anti-Fcm Fab¢, F(ab¢)2, and F(ab¢)3. Fab¢, F(ab¢)2, and F(ab¢)3 fragments were prepared from
M15/8 IgG as described in Materials and methods. Cells were incubated with antibody and [3H]thymidine as described in Figure 1. n n, irrelevant mAb; l, M15/8
IgG; s s, M15/8 Fab¢; l l, M15/8 F(ab¢)2; t, M15/8 F(ab¢)3. One of at least three similar experiments. Insert: Cells incubated with M15/8 Fab¢, F(ab¢)2, and F(ab¢)3
(10 mg ml–1) were analysed for DNA fragmentation as described in Materials and methods. Lane 1, untreated; lane 2, Fab¢; lane 3, F(ab¢)2; lane 4, F(ab¢)3;
lane 5, IgG; lane 6, molecular weight markers854 MS Cragg et al
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(Figure 4B) hyper-crosslinking of a single anti-Fcm mAb showed
less of an inhibitory effect, giving a maximum of 60% inhibition.
However, when a pair of non-crossblocking anti-Fcm mAb was
used (M15/8 + Mc41/24G10), the inhibitory effect of hyper-
crosslinking was again increased to 90%.
The effect of domain specificity of anti-IgM mAb on
growth inhibition
In the experiments described so far, the mAb used have been
directed to epitopes present in the Fc region of the m-chain
(Cm2–Cm4 domains). We have previously reported (Zhang et al,
1995) that compared with these, those mAb recognizing epitopes
present in the Fab arms of the IgM molecule (anti-Fdm, anti-L
chain, and anti-Id mAb) were comparatively poor in their ability to
transduce growth inhibitory signals in Burkitt’s cell lines. The
results were confirmed and are represented in Figure 5. The two
anti-Fdm mAb, XG9 and M-2E6, reduced growth by up to 25%,
compared with 65% for anti-Fcm mAb. The anti-l mAb,
Mc24/1C6 and M15/2, were also poor at causing growth inhibition
as were three mAb specific for the EHRB (Ramos) idiotype,
ZL16/1, ZL16/3, and ZL16/11. Crossblocking studies (results not
shown) revealed that two of the anti-Id mAb (ZL16/1 and ZL16/3)
recognized the same or proximal epitopes on surface IgM, but that
the third (ZL16/11) recognized a distinct epitope. In growth arrest
assays a mixture of either of the two non-crossblocking pairs,
ZL16/1 + ZL16/11 or ZL16/3 + ZL16/11, unlike the single
reagents or the crossblocking pair (ZL16/1 + ZL16/3), gave very
effective growth inhibition of up to 70%. To determine whether the
inhibitory activity of the single anti-Fdm, anti-L chain or anti-Id
mAb could be increased, the effect of hyper-crosslinking these
reagents was investigated. The results in Figure 6 show that
all types of anti-IgM mAb were highly effective at inducing
growth inhibition when hyper-crosslinked by a second layer of
polyclonal Ab.
Stoichiometry and affinity of mAb binding
We next determined the level of binding of 125I-labelled mAb to
EHRB cells; the plots in Figure 7A show the results obtained with
representative mAb of each specificity. IgG from the three anti-
Fcm mAb and the two anti-Fdm mAb gave similar saturation
curves and levels of binding, with between 15 and 20 ´ 104 mole-
cules of mAb binding to each cell. The binding affinities, esti-
mated from these curves, were also similar at around 1 ´ 109 M–1.
Surprisingly, however, IgG from three anti-Id mAb and the anti-l
chain mAb gave maximum levels of binding of between 35 and
40 ´ 104 molecules/cell, approximately twice that obtained with
the anti-Fcm and anti-Fdm mAb. Similar binding stoichiometry
was obtained with anti-Fcm and anti-Id mAb on Daudi cells
Irr
Antibody +/– hyper-crosslinking
100
75
50
25
[
3
H
]
t
h
y
m
i
d
i
n
e
 
i
n
c
o
r
p
o
r
a
t
i
o
n
 
(
%
 
c
o
n
t
r
o
l
)
M15/8 Mc41/24G10 Both
0
–+ –+ –+ –+
Irr
100
75
50
25
M15/8 Mc41/24G10
0
–+ –+ –+
A
B
Figure 4 Growth inhibition of EHRB and Daudi cells following hyper-
crosslinking of anti-Fcm mAb. EHRB (A) and Daudi (B) cells were incubated
with M15/8 (anti-Fcm) mAb at 10 mg ml–1 for 15 min. They were then harvested
by centrifugation, resuspended in medium with or without 20 mg ml–1 sheep
anti mouse IgG, incubated for 24 h at 37°C, and then pulsed overnight with
0.5 mCi/well [3H]thymidine. Cells were harvested and the incorporation of
radioactivity determined. The results represent mean ± SD for three
experiments for EHRB, and the average of two experiments for Daudi
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Figure 5 Comparison of growth inhibition of EHRB cells with mAb
recognizing different domains of surface IgM. Cells were incubated with mAb
and [3H]thymidine as described in Figure 1. n n, irrelevant mAb; l, M15/8
(anti-Fcm); s, M2E6 and XG9 (anti-Fdm); l l, Mc24/1C6 (anti-L chain) (M15/2,
another anti-L chain mAb gave a similar result); s s, ZL16/1, Zl16/3, and
ZL16/11 (anti-Ramos Id); t t, pairs of non-crossblocking anti-Id mAb. One of
three similar experimentsBinding of mAb to B-cell surface IgM 855
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(anti-Id mAb raised to Daudi IgM) and with anti-Fcm and anti-L
chain mAb on Namalwa cells (results not shown): i.e. anti-Id and
anti-L chain mAb bound approximately twice as many molecules
of mAb per cell as anti-Fcm mAb.
In view of these somewhat unexpected findings, we next
compared the binding of radiolabelled F(ab¢)2 and Fab¢ fragments
from the anti-Fcm mAb M15/8 (Figure 7B) and the anti-L chain
mAb Mc24/1C6 (Figure 7C). The results are represented as
Scatchard plots in Figure 7B and C. The binding pattern obtained
with the anti-Fcm mAb preparations (Figure 7B) were as expected,
with the F(ab¢)2 behaving very like the parent IgG with regard to
affinity of binding and the number of molecules bound to each
cell, and with the Fab¢ fragments having a lower affinity and
binding approximately twice as many molecules to each cell.
These results are consistent with two molecules of univalent Fab¢
binding to each molecule of surface IgM and one molecule of
bivalent F(ab¢)2 binding per surface IgM. In contrast, the affinity
and maximum level of binding obtained with F(ab¢)2 and Fab¢
from the anti-L chain mAb (Figure 7C) were both surprisingly
similar and close to the value obtained with the parent IgG. Thus
these results are consistent with the Mc24/1C6 IgG and F(ab¢)2
fragments binding univalently and so giving a 2:1 stoichiometry of
F(ab¢)2:surface IgM.
DISCUSSION
In this work we have investigated the ability of various anti-IgM
mAb to induce growth arrest and apoptosis of a number of Burkitt’s
cell lines. The preliminary screening showed that of eight lines
tested, only two, Ramos and Mutu-1, were sensitive to growth inhi-
bition by anti-Fcm mAb, and that Daudi cells, although not sensi-
tive to anti-Fcm mAb, showed inhibition in response to polyclonal
anti-IgM. The differential sensitivity of the lines to anti-IgM inhibi-
tion probably relates to a number of factors. George et al (1993)
have demonstrated that surface receptor number and density are
important criteria in B-cell signalling. Our results showing that
anti-m Ab, whether polyclonal or monoclonal, was unable to induce
growth inhibition in any of the low/medium IgM-expressing cell
lines tested (Namalwa, Raji, Bristol-8 and Nalm-6), support this
observation. This is in contrast to the reports from Rudich et al
(1988) and Mongini et al (1992) who demonstrated that BCR-
induced growth inhibition is much less dependent on receptor
density than is B-cell activation. The insensitivity of some of the
lines may also be related to their differentiation stage, as it is known
that BCR ligation only signals for inhibition at certain stages during
B-cell development, and may reflect the levels of anti- and pro-
apoptotic proteins present. The EBV status of the cells (Gregory et
al, 1991) and whether or not they possess FcR may also influence
their sensitivity to growth inhibition and apoptosis. The Ramos
EHRB sub-line selected for the main part of the project was exquis-
itely sensitive to anti-IgM-mAb-induced growth arrest and had the
advantage that it did not express FcR, and so the inhibitory
response could not be influenced by FcR:Fc interactions.
The two principle findings of the study were: 1) that the more
surface IgM was crosslinked by mAb, the more effective was the
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Figure 6 Growth inhibition of EHRB cells following hyper-crosslinking of
mAb recognizing different domains on surface IgM. Cells were incubated with
mAb followed by sheep anti-mouse IgG as described in Figure 4
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Figure 7 Binding of [125I]-labelled mAb to EHRB cells. (A) Serial dilutions of [125I]-labelled mAb were incubated with EHRB cells (1–2.5 ´ 106) for 2 h at 37°C.
The cells were then sedimented through phthalate oils and the pellet counted for radioactivity. The results are expressed as the number of antibody molecules
bound per cell. n n, irrelevant mAb; l, M15/8 (anti-Fcm); s, XG9, and H H, M2E6 (anti-Fdm); t t, ZL16/1, and H, ZL16/3 (both anti-Ramos Id); l l, Mc24/1C6 (anti-L
chain). One of at least three similar experiments. (B, C) Scatchard plots to compare the binding of F(ab¢)2 (n n) and Fab¢ (l) from M15/8 (B) and Mc24/1C6 (C) to
EHRB cells. B, molecules bound per cell (´ 10–4); F, free antibody concentration (M)856 MS Cragg et al
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resultant growth arrest and apoptosis; and 2) that the ability of a
single mAb to induce crosslinking was highly dependent on
epitope specificity. A range of experiments using anti-IgM mAb
(single or cocktails), polyclonal anti-m Ab, and hyper-crosslinking,
all showed that growth arrest of B-cell lines was highly dependent
on the extent of IgM crosslinking. These observations were
confirmed by varying the valency of the mAb by using Fab¢,
F(ab¢)2 and F(ab¢)3 derivatives from anti-Fcm mAb. Here the
progressive increase in valency resulted in a corresponding
decrease in cell proliferation, presumably as a result of more effi-
cient BCR-crosslinking on the cell surface. Furthermore, we were
able to show that cells treated with a trivalent F(ab¢)3 anti-m deriv-
ative underwent extensive DNA fragmentation indicating induc-
tion of apoptosis (insert to Figure 3).
Interestingly, the ability of single mAb to mediate IgM
crosslinking activity was dependent on their epitope specificity.
Thus, mAb directed at the Fc region (Cm2–Cm4 domains) of
surface IgM were much more effective at crosslinking B-cell IgM
and inducing growth arrest, than were those directed at Fab region
(anti-L chain, anti-Id and anti-Fdm) of this molecule. Only when
these latter mAb were hyper-crosslinked with polyclonal anti-
mouse IgG did they cause appreciable growth arrest and apoptosis.
Binding studies showed that this difference in function was not
related to any marked disparity in the affinity of the mAb studied
which were all in the range 1–4 ´ 109 M–1 (Figure 6). In view of the
results showing the importance of crosslinking in achieving growth
inhibition, this probably relates to the intrinsic crosslinking
capacity of the mAb, and depends on whether the anti-Fc and anti-
Fab mAb bind to surface IgM bigamously or monogamously (Elliot
et al, 1987). mAb that bind bigamously, with epitopes or adjacent
BCR complexes, form effective inter-BCR crosslinks, and those
that bind monogamously, with the epitopes on a single surface IgM
molecule, have poor crosslinking capacity. Rudich et al (1988) have
provided evidence using immunoelectron microscopy that whereas
the anti-Fdm mAb XG9, used in this study, binds in a predominantly
monogamous manner, an anti-Fcm mAb, 1G6, binds predominantly
bigamously. This could explain the inefficacy of XG9 in our assays
and supports the hypothesis that bigamous binding is a requirement
for BCR-induced growth inhibition. Grafton et al (1997) have
recently published a study using a large panel of anti-IgM mAb
recognizing the Cm2–Cm4 domains of the Fc region. They show
that most of these mAb were able to induce growth inhibition;
interestingly, although the panel did not include any mAb recog-
nizing the anti-Fdm region (Cml domain), two anti-Id mAb in the
panel failed to cause growth inhibition.
Although initially the lack of efficacy of the anti-L chain and
anti-Id mAb was also attributed to a predominantly monogamous
type binding, the results of the 125I-labelled mAb binding experi-
ments suggested an alternative explanation (Figure 7). The
maximum level of binding to EHRB cells obtained with IgG from
the anti-L chain and anti-Id mAb was twice that obtained with the
anti-Fcm and anti-Fdm mAb. Similar results were obtained with
anti-Id mAb on Daudi cells and anti-L chain mAb on Namalwa
cells. Assuming that the stoichiometry of anti-Fdm and anti-Fcm
mAb binding to surface IgM molecule is 1:1, this suggests that two
molecules of anti-L chain or anti-Id mAb were bound per surface
IgM, and therefore favours the idea that their binding was predom-
inantly univalent rather than bivalent, and that this is the reason
for their poor growth inhibitory capacity. The comparison of the
binding of F(ab¢)2 and Fab¢ fragments (Figure 7) was consistent
with this interpretation, since, in contrast to the results obtained
with fragments from the anti-Fcm mAb M15/8, Fab¢ and F(ab¢)2
from anti-L chain mAb gave a similar value for maximum binding
and binding affinity.
In view of the therapeutic success of anti-Id mAb in certain B-
cell malignancies (Vuist et al, 1994; Racila et al, 1995; Tutt et al,
1998), the inability of any of the three anti-Ramos Id mAb (and
two for Daudi) to cause growth inhibition in vitro was somewhat
surprising. This is particularly important because there is growing
support for the idea that a number of therapeutic anti-lymphoma
mAb, including anti-Id and anti-CD20, may be operating via a
direct signalling route, rather than by the recruitment of cytotoxic
effector cells (Tutt et al, 1998). However, our results showed that
irrespective of the ability of an individual mAb to induce growth
inhibition, after hyper-crosslinking all mAb were equally potent.
The ability of anti-Id mAb to induce transmembrane signalling and
growth arrest in vivo is probably dependent on a number of factors
other than their intrinsic crosslinking activity, which we have
measured. For example, we can expect that FcR-bearing effector
cells might play an important role in delivering hyper-crosslinking
to anti-Id mAb-coated target cells. In this situation many FcR-
carrying cells such as NK-cells, monocytes, neutrophils, endothe-
lial cells or perhaps even B-cells would be effective at delivering
cytotoxic signal. Thus effector cells would not necessarily need to
be cytotoxic in themselves, but would simply need to deliver a
multivalent array of FcR to hyper-crosslink the BCR. In support of
this suggestion, recent work from Shan et al (1998) shows that
the ability of another apoptosis-inducing mAb, anti-CD20, is
markedly enhanced by the addition of FcR-bearing effector cells to
the cultures. The presence of FcR-bearing cells has also been
shown to enable a mAb recognizing CD79b, a signalling compo-
nent of the BCR, to induce inhibitory signals (Van Kooten et al,
1997). The results presented here show that in vitro most anti-Id
mAb are particularly ineffective at crosslinking the BCR to
mediate growth arrest, suggesting that their success in vivo prob-
ably require an additional form of crosslinking.
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